ArticlePediatric research2026
Downregulation of pigment epithelium-derived factor increases compensatory lung growth in mice after extended pneumonectomy.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Michelle Lim: ECI biocommentary.Pediatric research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary hypoplasia following lung resection for congenital conditions (lobar emphysema or sequestration) may involve significant tissue loss. Previously, our lab demonstrated that FG-4592, a prolyl hydroxylase inhibitor, accelerates murine compensatory lung growth (CLG) following left pneumonectomy (LP). In this study, we investigated FG-4592 in a more severe disease model involving removal of both the left lung and right caval lobe (extended pneumonectomy; EP) which is characterized by decreased CLG.
methodsEP was performed in mice, followed by treatment with FG-4592. Lung regeneration was assessed at postoperative day (POD) 8 and 14 using pulmonary function tests, exercise tolerance testing, histologic analysis of alveolarization and angiogenesis. Pigment epithelium-derived factor (PEDF) knockout mice were used to explore the mechanism of FG-4592-induced angiogenesis.
resultsFG-4592 treatment significantly improved lung function and exercise tolerance at POD 8, with sustained benefits observed at POD 14. Enhanced alveolarization and angiogenesis were noted. Experiments utilizing PEDF knockout mice confirmed that FG-4592-induced angiogenesis is driven by PEDF downregulation.
conclusionFG-4592 increases lung regeneration following EP by promoting alveolar and vascular growth, mediated in part by PEDF downregulation. These findings support FG-4592 as a potential therapeutic candidate in conditions where CLG is required for recovery of lung function. IMPACT: FG-4592 increases lung function and growth in a murine model of severe compensatory lung growth The current study expands on our understanding of FG-4592 and establishes its efficacy in a more severe model than previously tested FG-4592 increases angiogenic signaling through the vascular endothelial growth factor receptor 2, a pathway that is important in lung growth and development FG-4592 is expected to have efficacy in both male and female pediatric patients with severe pulmonary hypoplasia after lung resection.
Identifiers
41851496What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.